It goes one step further as a triple-agonist, targeting GLP-1, GIP, and glucagon receptors, which may enhance fat metabolism
This strategy is used for PEG-Loxenatide from Haosen Pharmaceutical
Short-acting GLP-1RAs, such as lixisenatide, maintain robust effects on gastric emptying, whereas long-acting agents, like liraglutide and semaglutide, exhibit reduced efficacy due to continuous receptor activation
Not just nausea Another side effect of GLP-1 drugs is a decrease in thirst, which could be dangerous for people who are already losing lots of fluids from side effects like vomiting and diarrhea
Mounjaro EPAR Product Information (INN: tirzepatide)
Liver Disease: MASLD and NAFLD Metabolic dysfunction-associated steatotic liver disease (MASLD formerly NAFLD) affects approximately 1 in 3 UK adults with obesity